Nordic Pharma’s Lacrifill Canalicular Gel Recognized in TFOS DEWS III Report

Nordic Pharma, a subsidiary of Nordic Group BV, has announced that its Lacrifill Canalicular Gel, a novel therapy designed to relieve dry eye symptoms, has been featured in the Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS).

The TFOS DEWS III report, published in the June 2025 issue of the American Journal of Ophthalmology, cites two clinical studies on Nordic Pharma’s crosslinked hyaluronic acid (HA) canalicular filler in Section 6.2.4, “Newer Plug Designs and Other Technologies.”

Clinical Evidence Cited in DEWS III

The first study demonstrated improvements in corneal staining, Schirmer test scores, and other key dry eye measures three months after treatment.

In the second study, Lacrifill Canalicular Gel was compared to a commercially available hydrogel canalicular plug and was found to be safe, well-tolerated, and capable of delivering statistically significant symptom and sign improvements that were sustained over six months.

Upcoming Presentation at WIO Summer Symposium

Lacrifill research will be highlighted at the Women in Ophthalmology (WIO) Summer Symposium from August 7–10.

Monica Patel, MD, founder and Medical Director of Clear Vision Ophthalmology, will present a poster titled: “Evaluation of Lacrimal Punctal Plug Insertion for Dry Eye Relief in Ophthalmology Clinic Patients Using Self-Reported Improvement and OSDI Questionnaires.”

Key Findings from Dr. Patel’s Study

In Dr. Patel’s study (117 patients, 1 month after Lacrifill placement), 66.25% of patients reported at least 50% symptom improvement one month after Lacrifill placement. Most of these individuals experienced 90–100% improvement, particularly in burning and “sandiness” sensations. Notably, benefits were observed across all patient subgroups, including those with comorbidities such as diabetes, thyroid disease, and glaucoma.

Dr. Patel emphasized the importance of correlating subjective patient reports with Ocular Surface Disease Index (OSDI) scores, noting that self-reported outcomes can be a valid and efficient tool for evaluating new therapies.

“This is a well-done, real-time study demonstrating consistent efficacy in symptom relief,” said Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care U.S.

Case Studies Reinforcing Lacrifill’s Benefits

Two recent case reports further support Lacrifill’s effectiveness:

       • Post–Refractive Cataract Surgery (Jennifer Loh, MD, CRST, June 2025): In a patient with post-surgical blurriness unresponsive to conventional treatments, Lacrifill improved both uncorrected visual acuity and visual quality by stabilizing the tear film.

       • Dry Eye Disease with Demodex Blepharitis (Selina McGee, OD, FAAO, Modern Optometry, May/June 2025): Treatment led to significant SPEED score improvement, resolution of inferior corneal staining, and an increase in tear meniscus height.